{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:58:07Z","timestamp":1794855487742,"version":"4.9.1"},"reference-count":85,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>\n                    To evaluate the relationship between testosterone replacement therapy (TRT) and arterial and\/or venous thrombosis in patients with pre-treatment total testosterone (TT) &lt;12 nmol l\n                    <jats:sup>\u22121<\/jats:sup>\n                    , we performed a meta-analysis following the Population Intervention Comparison Outcome model. Population: men with TT &lt;12 nmol l\n                    <jats:sup>\u22121<\/jats:sup>\n                    or clear mention of hypogonadism in the inclusion criteria of patients; intervention: TRT; comparison: placebo or no therapy; outcomes: arterial thrombotic events (stroke, myocardial infarction [MI], upper limbs, and lower limbs), VTE (deep vein thrombosis [DVT], portal vein thrombosis, splenic thrombosis, and pulmonary embolism), and mortality. A total of 2423 abstracts were assessed for eligibility. Twenty-four studies, including 14 randomized controlled trials (RCTs), were finally included, with a total of 4027 and 310 288 hypotestosteronemic male patients, from RCTs and from observational studies, respectively. Based on RCT-derived data, TRT did not influence the risk of arterial thrombosis (odds ratio [OR] = 1.27, 95% confidence interval [CI]: 0.47\u20133.43,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.64), stroke (OR = 1.34, 95% CI: 0.09\u201318.97,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.83), MI (OR = 0.51, 95% CI: 0.11\u20132.31,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.39), VTE (OR = 1.42, 95% CI: 0.22\u20139.03,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.71), pulmonary embolism (OR = 1.38, 95% CI: 0.27\u20137.04,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.70), and mortality (OR = 0.70, 95% CI: 0.20\u20132.38,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.56). Meanwhile, when only observational studies are considered, a significant reduction in the risk of developing arterial thrombotic events, MI, venous thromboembolism, and mortality was observed. The risk for DVT remains uncertain, due to the paucity of RCT-based data. TRT in men with TT &lt;12 nmol l\n                    <jats:sup>\u22121<\/jats:sup>\n                    is safe from the risk of adverse cardiovascular events. Further studies specifically assessing the risk of DVT in men on TRT are needed.\n                  <\/jats:p>","DOI":"10.4103\/aja202352","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:00:08Z","timestamp":1698638408000},"page":"144-154","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["Testosterone replacement therapy and vascular thromboembolic events: a systematic review and meta-analysis"],"prefix":"10.4103","volume":"26","author":[{"given":"Rossella","family":"Cannarella","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy"},{"name":"Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Gusmano","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Leanza","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Garofalo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Crafa","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Barbagallo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosita A","family":"Condorelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro La","family":"Vignera","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo E","family":"Calogero","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism:an endocrine society clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5694\/mja16.00393","article-title":"Endocrine Society of Australia position statement on male hypogonadism (Part 1):assessment and indications for testosterone therapy","volume":"205","author":"Yeap","year":"2016","journal-title":"Med J Aust"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ucl.2016.01.002","article-title":"Hypogonadism:its prevalence and diagnosis","volume":"43","author":"Ross","year":"2016","journal-title":"Urol Clin North Am"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2021.06.007","article-title":"European Association of Urology guidelines on sexual and reproductive health-2021 update:male sexual dysfunction","volume":"80","author":"Salonia","year":"2021","journal-title":"Eur Urol"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1007\/s40618-022-01859-7","article-title":"Adult- and late-onset male hypogonadism:the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE)","volume":"45","author":"Isidori","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"R6-20240829","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2013.280386","article-title":"Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels","volume":"310","author":"Vigen","year":"2013","journal-title":"JAMA"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","article-title":"Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men","volume":"9","author":"Finkle","year":"2014","journal-title":"PLoS One"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.21037\/tau.2019.04.03","article-title":"Changes in testosterone prescribing patterns after FDA warning","volume":"8","author":"Lokeshwar","year":"2019","journal-title":"Transl Androl Urol"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"e015284","DOI":"10.1136\/bmjopen-2016-015284","article-title":"Testosterone therapy in hypogonadal men:a systematic review and network meta-analysis","volume":"7","author":"Elliott","year":"2017","journal-title":"BMJ Open"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jsxm.2018.04.641","article-title":"Testosterone and cardiovascular risk:meta-analysis of interventional studies","volume":"15","author":"Corona","year":"2018","journal-title":"J Sex Med"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/andr.12770","article-title":"European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology","volume":"8","author":"Corona","year":"2020","journal-title":"Andrology"},{"key":"R12-20240829","doi-asserted-by":"crossref","first-page":"l476","DOI":"10.1136\/bmj.l476","article-title":"Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: Mendelian randomisation study in UK Biobank","volume":"364","author":"Luo","year":"2019","journal-title":"BMJ"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/bloodadvances.2018024828","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism:diagnosis of venous thromboembolism","volume":"2","author":"Lim","year":"2018","journal-title":"Blood Adv"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jamainternmed.2019.5135","article-title":"Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism","volume":"180","author":"Walker","year":"2020","journal-title":"JAMA Intern Med"},{"key":"R15-20240829","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.thromres.2020.12.029","article-title":"Testosterone replacement therapy and the risk of venous thromboembolism:a systematic review and meta-analysis of randomized controlled trials","volume":"199","author":"Ayele","year":"2021","journal-title":"Thromb Res"},{"issue":"11","key":"R16-20240829","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1741-7015-11-108","article-title":"Testosterone therapy and cardiovascular events among men:a systematic review and meta-analysis of placebo-controlled randomized trials","volume":"18","author":"Xu","year":"2013","journal-title":"BMC Med"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2666-7568(22)00096-4","article-title":"Adverse cardiovascular events and mortality in men during testosterone treatment:an individual patient and aggregate data meta-analysis","volume":"3","author":"Hudson","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"R18-20240829","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology:a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"R19-20240829","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015:elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R20-20240829","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER:a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"R21-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11292-008-9066-0","article-title":"Drawing conclusions about causes from systematic reviews of risk factors:the Cambridge quality checklists","volume":"5","author":"Murray","year":"2009","journal-title":"J Exp Criminol"},{"key":"R22-20240829","first-page":"1","article-title":"RoB 2:a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R23-20240829","first-page":"89","article-title":"A nonparametric \u201ctrim and fill\u201dmethod of accounting for publication bias in meta-analysis","volume":"95","author":"Duval","year":"2000","journal-title":"J Am Stat Assoc"},{"key":"R24-20240829","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3109\/13685538.2012.699562","article-title":"A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up","volume":"15","author":"Behre","year":"2012","journal-title":"Aging Male"},{"key":"R25-20240829","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0002-9343(01)00813-0","article-title":"Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age","volume":"111","author":"Snyder","year":"2001","journal-title":"Am J Med"},{"key":"R26-20240829","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1210\/jc.2012-3695","article-title":"Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels","volume":"98","author":"Hildreth","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R27-20240829","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12916-016-0700-9","article-title":"Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet:a randomised controlled trial","volume":"14","author":"Ng Tang Fui","year":"2016","journal-title":"BMC Med"},{"key":"R28-20240829","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration","volume":"363","author":"Basaria","year":"2010","journal-title":"N Engl J Med"},{"key":"R29-20240829","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2007.51","article-title":"Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men:a randomized controlled trial","volume":"299","author":"Emmelot-Vonk","year":"2008","journal-title":"JAMA"},{"key":"R30-20240829","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1111\/j.1743-6109.2010.01931.x","article-title":"Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome:results from a 24-month, randomized, double-blind, placebo-controlled study","volume":"7","author":"Aversa","year":"2010","journal-title":"J Sex Med"},{"key":"R31-20240829","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1464-410X.2011.10755.x","article-title":"A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the aging male symptoms scale","volume":"110","author":"Ho","year":"2012","journal-title":"BJU Int"},{"key":"R32-20240829","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/ijcp.12876","article-title":"Testosterone treatment is not associated with increased risk of adverse cardiovascular events:results from the Registry of Hypogonadism in Men (RHYME)","volume":"70","author":"Maggi","year":"2016","journal-title":"Int J Clin Pract"},{"key":"R33-20240829","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.urology.2015.03.049","article-title":"Association between testosterone supplementation therapy and thrombotic events in elderly men","volume":"86","author":"Ramasamy","year":"2015","journal-title":"Urology"},{"key":"R34-20240829","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/1074248417691136","article-title":"Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism:a real-life observational registry study setting comparing treated and untreated (control) groups","volume":"22","author":"Traish","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R35-20240829","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1080\/13685538.2020.1867094","article-title":"Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men:a prospective controlled registry study","volume":"23","author":"Yassin","year":"2020","journal-title":"Aging Male"},{"key":"R36-20240829","doi-asserted-by":"crossref","first-page":"e020562","DOI":"10.1161\/JAHA.120.020562","article-title":"Association between testosterone treatment and risk of incident cardiovascular events among US male veterans with low testosterone levels and multiple medical comorbidities","volume":"10","author":"Shores","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"R37-20240829","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.juro.2015.10.083","article-title":"Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men:results of a placebo controlled study","volume":"195","author":"Brock","year":"2016","journal-title":"J Urol"},{"key":"R38-20240829","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/jama.2015.8881","article-title":"Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels:a randomized clinical trial","volume":"314","author":"Basaria","year":"2015","journal-title":"JAMA"},{"key":"R39-20240829","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamainternmed.2016.9546","article-title":"Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency","volume":"177","author":"Cheetham","year":"2017","journal-title":"JAMA Intern Med"},{"key":"R40-20240829","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.juro.2016.04.065","article-title":"9-month efficacy and safety study of testosterone solution 2% for sex drive and energy in hypogonadal nen","volume":"196","author":"Brock","year":"2016","journal-title":"J Urol"},{"key":"R41-20240829","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.chest.2016.05.007","article-title":"Association between testosterone replacement therapy and the incidence of DVT and pulmonary embolism:a retrospective cohort study of the Veterans Administration Database","volume":"150","author":"Sharma","year":"2016","journal-title":"Chest"},{"key":"R42-20240829","doi-asserted-by":"crossref","first-page":"e1096","DOI":"10.1210\/clinem\/dgaa917","article-title":"Testosterone replacement therapy added to intensive lifestyle intervention in older men with obesity and hypogonadism","volume":"106","author":"Barnouin","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R43-20240829","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/bju.12037","article-title":"Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men:a randomised controlled study","volume":"111","author":"Tan","year":"2013","journal-title":"BJU Int"},{"key":"R44-20240829","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1210\/jc.2009-1251","article-title":"Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men:a randomized, double-blind, placebo-controlled study","volume":"95","author":"Srinivas-Shankar","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R45-20240829","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-13-0321","article-title":"Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes","volume":"169","author":"Muraleedharan","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"R46-20240829","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ijir.2014.29","article-title":"Testosterone therapy and mortality risk","volume":"27","author":"Eisenberg","year":"2015","journal-title":"Int J Impot Res"},{"key":"R47-20240829","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/CIRCULATIONAHA.107.719005","article-title":"Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study","volume":"116","author":"Khaw","year":"2007","journal-title":"Circulation"},{"key":"R48-20240829","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1210\/jc.2008-2416","article-title":"Lower testosterone levels predict incident stroke and transient ischemic attack in older men","volume":"94","author":"Yeap","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R49-20240829","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.mayocp.2015.05.012","article-title":"Risk of venous thromboembolism in men receiving testosterone therapy","volume":"90","author":"Baillargeon","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"R50-20240829","doi-asserted-by":"crossref","first-page":"i5968","DOI":"10.1136\/bmj.i5968","article-title":"Testosterone treatment and risk of venous thromboembolism:population based case-control study","volume":"355","author":"Martinez","year":"2016","journal-title":"BMJ"},{"key":"R51-20240829","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.2047-2927.2014.00241.x","article-title":"Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events","volume":"2","author":"Corona","year":"2014","journal-title":"Andrology"},{"key":"R52-20240829","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1530\/EJE-08-0888","article-title":"Endogenous sex hormone levels in men are not associated with risk of venous thromboembolism:the Tromso study","volume":"160","author":"Svartberg","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"R53-20240829","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/jth.12484","article-title":"Endogenous sex hormones and risk of venous thromboembolism in women and men","volume":"12","author":"Holmegard","year":"2014","journal-title":"J Thromb Haemost"},{"key":"R54-20240829","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-014-0211-5","article-title":"Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration:a systematic review and meta-analysis","volume":"12","author":"Borst","year":"2014","journal-title":"BMC Med"},{"key":"R55-20240829","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12874-016-0136-0","article-title":"Meta-analyses including non-randomized studies of therapeutic interventions:a methodological review","volume":"16","author":"Faber","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"R56-20240829","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/gerona\/60.11.1451","article-title":"Adverse events associated with testosterone replacement in middle-aged and older men:a meta-analysis of randomized, placebo-controlled trials","volume":"60","author":"Calof","year":"2005","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R57-20240829","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.2174\/1381612826666201102105408","article-title":"Cardiovascular complications in patients with Klinefelter's syndrome","volume":"26","author":"Sesti","year":"2020","journal-title":"Curr Pharm Des"},{"key":"R58-20240829","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/0002-8703(94)90679-3","article-title":"Hematocrit and the risk of cardiovascular disease \u2013the Framingham study:a 34-year follow-up","volume":"127","author":"Gagnon","year":"1994","journal-title":"Am Heart J"},{"key":"R59-20240829","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and management of testosterone deficiency: AUA guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"key":"R60-20240829","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4158\/EP.8.6.439","article-title":"American Association of Clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients \u20132002 update","volume":"8","author":"Petak","year":"2002","journal-title":"Endocr Pract"},{"key":"R61-20240829","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.jsxm.2017.10.067","article-title":"British Society for Sexual Medicine guidelines on adult testosterone deficiency, with statements for UK practice","volume":"14","author":"Hackett","year":"2017","journal-title":"J Sex Med"},{"key":"R62-20240829","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.jsxm.2016.10.009","article-title":"Diagnosis and treatment of testosterone deficiency:recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015)","volume":"13","author":"Khera","year":"2016","journal-title":"J Sex Med"},{"key":"R63-20240829","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/13685538.2015.1004049","article-title":"Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men","volume":"18","author":"Lunenfeld","year":"2015","journal-title":"Aging Male"},{"key":"R64-20240829","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.amjmed.2020.07.037","article-title":"Risks of serious injury with testosterone treatment","volume":"134","author":"Yarnell","year":"2021","journal-title":"Am J Med"},{"key":"R65-20240829","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.esxm.2020.01.009","article-title":"Occurrence of pulmonary oil microembolism after testosterone undecanoate injection:a postmarketing safety analysis","volume":"8","author":"Pastuszak","year":"2020","journal-title":"Sex Med"},{"key":"R66-20240829","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/bmjsrh-2018-200206","article-title":"Assessing safety in hormonal male contraception:a critical appraisal of adverse events reported in a male contraceptive trial","volume":"46","author":"Abbe","year":"2020","journal-title":"BMJ Sex Reprod Health"},{"key":"R67-20240829","doi-asserted-by":"crossref","first-page":"2324709616661833","DOI":"10.1177\/2324709616661833","article-title":"Four thrombotic events over 5 years, two pulmonary emboli and two deep venous thrombosis, when testosterone-hCG therapy was continued despite concurrent anticoagulation in a 55-year-old man with lupus anticoagulant","volume":"4","author":"Glueck","year":"2016","journal-title":"J Investig Med High Impact Case Rep"},{"key":"R68-20240829","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/1076029615619486","article-title":"Thrombophilia in 67 patients with thrombotic wvents after starting testosterone therapy","volume":"22","author":"Glueck","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"R69-20240829","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.juro.2015.10.134","article-title":"Association between use of exogenous testosterone therapy and risk of venous thrombotic events among exogenous testosterone treated and untreated men with hypogonadism","volume":"195","author":"Li","year":"2016","journal-title":"J Urol"},{"key":"R70-20240829","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/MBC.0000000000000126","article-title":"Testosterone, thrombophilia, thrombosis","volume":"25","author":"Glueck","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R71-20240829","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1076029613485154","article-title":"Testosterone, thrombophilia, and thrombosis","volume":"20","author":"Glueck","year":"2014","journal-title":"Clin Appl Thromb Hemost"},{"key":"R72-20240829","first-page":"251","article-title":"Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy:observational, real-life data from a registry study","volume":"12","author":"Haider","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"R73-20240829","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/j.1743-6109.2011.02265.x","article-title":"Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men","volume":"8","author":"Kaufman","year":"2011","journal-title":"J Sex Med"},{"key":"R74-20240829","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1365-2265.2010.03845.x","article-title":"Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome:the double-blinded placebo-controlled Moscow study","volume":"73","author":"Kalinchenko","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R75-20240829","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/phar.1534","article-title":"Testosterone therapy and risk of myocardial infarction:a pharmacoepidemiologic study","volume":"35","author":"Etminan","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R76-20240829","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/eurheartj\/ehv346","article-title":"Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men","volume":"36","author":"Sharma","year":"2015","journal-title":"Eur Heart J"},{"key":"R77-20240829","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.mayocpiqo.2017.05.003","article-title":"Normalization of testosterone levels after testosterone replacement therapy is not associated with reduced myocardial infarction in smokers","volume":"1","author":"Oni","year":"2017","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"R78-20240829","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1177\/1060028014539918","article-title":"Risk of myocardial infarction in older men receiving testosterone therapy","volume":"48","author":"Baillargeon","year":"2014","journal-title":"Ann Pharmacother"},{"key":"R79-20240829","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1532-5415.2010.02865.x","article-title":"Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty","volume":"58","author":"Kenny","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"R80-20240829","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa054629","article-title":"DHEA in elderly women and DHEA or testosterone in elderly men","volume":"355","author":"Nair","year":"2006","journal-title":"N Engl J Med"},{"key":"R81-20240829","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older men","volume":"374","author":"Snyder","year":"2016","journal-title":"N Engl J Med"},{"key":"R82-20240829","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jsxm.2022.05.145","article-title":"Cardiovascular morbidity and mortality in men \u2013findings from a meta-analysis on the time-related measure of risk of exogenous testosterone","volume":"19","author":"Fallara","year":"2022","journal-title":"J Sex Med"},{"key":"R83-20240829","doi-asserted-by":"crossref","first-page":"418","DOI":"10.23736\/S2724-6051.21.04307-X","article-title":"Testosterone replacement therapy in hypogonadal male patients with hypogonadism and heart failure:a meta-analysis of randomized controlled studies","volume":"74","author":"Cannarella","year":"2022","journal-title":"Minerva Urol Nephrol"},{"key":"R84-20240829","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41443-019-0163-6","article-title":"Effect of treatment with testosterone on endothelial function in hypogonadal men:a systematic review and meta-analysis","volume":"32","author":"Sansone","year":"2020","journal-title":"Int J Impot Res"},{"key":"R85-20240829","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1530\/EJE-11-0447","article-title":"Hypogonadism as a risk factor for cardiovascular mortality in men:a meta-analytic study","volume":"165","author":"Corona","year":"2011","journal-title":"Eur J Endocrinol"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:42:10Z","timestamp":1787067730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/aja202352","relation":{},"ISSN":["1745-7262","1008-682X"],"issn-type":[{"value":"1745-7262","type":"print"},{"value":"1008-682X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]},"assertion":[{"value":"2023-03-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}